Here are three points:
1. On April 18, the company’s share volume reached 11.11 million shares.
2. Under the partnership, Weigao Orthopedic will have exclusive marketing and distribution rights for the Amedica brand silicon nitride spinal implants in China.
3. Weigao Orthopedic will abide by the minimum purchase requirements for the implants during the first year of the agreement, which is 20,000 units. However, the company expects to grow its purchases to 50,000 units by the sixth year.
More articles on devices:
Baird rates Exactech as ‘outperform’: 4 insights
VerteCore finishes 1st week of Lift device crowdfunding: 3 points
Orthofix shares reach new 1-year high: 3 points
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
